论文部分内容阅读
目的 :探讨吉非罗齐对 2型糖尿病血脂、血糖代谢的影响。方法 :在维持原糖尿病治疗方案的同时 ,将 5 1例 2型糖尿病伴有高脂血症的患者分为 2组。治疗组 31例予吉非罗齐胶囊 45 0mg ,每日 2次口服 ,对照组 2 0例不服吉非罗齐。结果 :治疗后 3个月 ,治疗组总胆固醇 (TC)、甘油三酯 (TG)、低密度脂蛋白胆固醇(LDL C)及空腹血糖 (FBG)均明显下降 (P <0 0 0 1或P <0 0 1) ,高密度脂蛋白胆固醇 (HDL C)显著增高 (P <0 0 1)。对照组各项指标无显著变化 (P >0 0 5 )。结论 :吉非罗齐治疗伴有高脂血症的糖尿病患者 ,不仅能使TC ,TG ,LDL C下降 ,HDL C升高 ,改善脂质代谢 ,还能改善糖代谢 ,使FBG下降。
Objective: To investigate the effect of gemfibrozil on blood lipid and glucose metabolism in type 2 diabetic patients. Methods: 51 untreated type 2 diabetic patients with hyperlipidemia were divided into two groups while maintaining the original diabetic regimen. In the treatment group, 31 cases were given gemfibrozil capsules 45 0 mg orally twice daily and in the control group 20 cases were not given gemfibrozil. Results: At 3 months after treatment, the total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL C) and fasting blood glucose (FBG) were significantly decreased in the treatment group (P <0.01 or P <0 01), HDL C was significantly higher (P <0.01). There was no significant change in the control group (P> 0.05). Conclusion: Gemfibrozil treatment of diabetic patients with hyperlipidemia can not only lower TC, TG, LDL C, increase HDL C, improve lipid metabolism, but also improve glucose metabolism and decrease FBG.